Pharma BD Deal Intelligence
On February 25, 2026, Novo Nordisk and Vivtex Corporation (an MIT/Robert Langer-founded biotech) announced a global technology licensing partnership to develop next-generation ORAL biologic medicines for obesity, type 2 diabetes and associated metabolic comorbidities. Vivtex licenses its proprietary GI-ORIS gastrointestinal screening and oral drug-delivery platform - which pairs physiologically relevant GI assays with AI/computational modeling to optimize oral bioavailability of peptide and protein therapeutics traditionally limited to injection. Vivtex is eligible for an undisclosed upfront payment plus research funding, development and commercial milestones totaling up to $2.1 billion, and tiered royalties on future net sales; Novo Nordisk assumes global development, manufacturing, regulatory and commercialization responsibility. The deal extends Novo's oral-obesity strategy amid looming semaglutide generics and the CagriSema setback.